

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 43

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 43

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 43

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

An ongoing review is under way of the long-standing objections to proposed International Nonproprietary Names (INN). As a result, objections have been withdrawn to the following names which are now included in this list of recommended INNs:

atizoram, atliprofen, beclamide, bicifadine, bornelone, ciadox, cloperastine, clorexolone, cloroperone, corticotropin zinc hydroxide, cresotamide, difenidol, diosmin, divabuterol, eledoisin, eritrityl tetranitrate, exepanol, fenaclon, fenoprofen, fluquazone, glutaurine, guaifylline, halazone, kebuzone, metamfepramone, meticillin, moquizone, nabilone, nonabine, norgesterone, odalprofen, oletimol, pentiapine, plauracin, sulisatin, tandamine, teoprانيتol, ticarcillin, tienocarbine, triclofos, triflocin, trimecaine, zolazepam

Les objections formulées de longue date contre des Dénominations communes internationales (DCI) proposées sont examinées. Des objections ont été retirées à la suite de cet examen et les noms suivants sont donc inclus dans cette liste des DCI recommandées:

atizoram, atliprofène, béclamide, bicifadine, bornélone, ciadox, clopéastine, clorexolone, cloropérone, corticotropine hydroxyde de zinc, crésotamide, difénidol, diosmine, divabutérol, élédoïsine, tétranitrate d'éritrityle, exépanol, fénaclone, fénoprofène, fluquazone, glutaurine, guaïfylline, halazone, kébuzone, métamfépramone, méticilline, moquizone, nabilone, nonabine, norgestérone, odalprofène, olétimol, pentiapine, plauracine, sulisatine, tandamine, téoprانيتol, ticarcilline, tiénocarbine, triclofos, triflocine, trimécaïne, zolazépam

Se ha emprendido un examen de las objeciones que se vienen formulando desde hace tiempo a las denominaciones comunes internacionales (DCI) propuestas. Como resultado, se han retirado las objeciones a las denominaciones siguientes, que ahora están incluidas en la presente lista de DCI recomendadas:

atizoram, atliprofeno, beclamida, bicifadina, bornelona, ciadox, cloperastina, clorexolona, cloroperona, corticotropina hidróxido de zinc, cresotamida, difenidol, diosmina, divabuterol, eledoisina, tetranitrato de eritritilo, exepanol, fenaclón, fenoprofeno, flucua zona, glutaurina, guaifilina, halazona, kebuzona, metanfep ramona, metecilina, moquizona, nabilona, nonabina, norgesterona, odalprofeno, oletimol, pentiapina, plauracina, sulisatina, tandamina, teoprانيتol, ticarcilina, tienocarbina, triclofós, triflocina, trimecaína, zolazepam

Proposed INN
(Latin, English, French, Spanish)

Chemical name or description: Action and use: Molecular formula
Chemical Abstracts Service (CAS) registry number: Graphic formula

DCI Proposée

Nom chimique ou description: Propriétés et indications: Formule brute
Numéro dans le registre du CAS: Formule développée

DCI Propuesta

Nombre químico o descripción: Acción y uso: Fórmula empírica
Número de registro del CAS: Fórmula desarrollada

abetimusum

abetimus

d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)-P, 5',5'',5''',5''''-tetraester with ethylenebis(oxyethylene) bis[bis[2-[6-[2-[(6-hydroxyhexyl)thio]=acetamido]hexanamido]ethyl]carbamate], complex with d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) (1:4)


abétimus

complexe (4:1) entre l'acide désoxyribonucléique d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) et le tétrakis[5'-hydrogénophosphate de l'acide désoxyribonucléique d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)] de 6,6',6'',6'''-[éthylènebis[oxyéthylèneoxycarbonylnitrilobis[éthylèneimino=(6-oxohexane-6,1-diyl)imino(2-oxoéthane-2,1-diyl)sulfanediy]]]tétrahexyle

abetimús

5',5'',5''',5''''-P-tetraéster del d(P-tetraéster del d(C-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A) con bis[bis[2-[6-[2-[(6-hidroxihehexil)tio]acetamido]=hexanamido]etil]carbamato] de etilenobis(oxietileno), complejo con d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) (1:4)

C₁₆₃₂H₂₁₀₀N₆₁₀O₉₇₀P₁₅₆S₄



acidum caloxeticum


caloxetic acid

trihydrogen [*N*-[(2*S*)-2-[bis(carboxymethyl)amino]-3-(*p*-ethoxyphenyl)propyl]-*N*-2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]calcite(3-)

acide caloxétique

trihydrogène [*N*-[(2*S*)-2-[bis(carboxyméthyl)amino]-3-(4-éthoxyphényl)propyl]-*N*-2-[bis(carboxyméthyl)amino]éthyl]glycinato(5-)]calciato(3-)

ácido caloxético

[*N*-[(2*S*)-2-[bis(carboximetil)amino]-3-(*p*-etoxifenil)propil]-*N*-2-[bis(carboximetil)amino]etil]glicinato(5-)]calciato(3-) de trihidrógenoC₂₃H₃₁CaN₃O₁₁**anidulafunginum**

anidulafungin


(4*R*,5*R*)-4,5-dihydroxy-*N*²-[[4''-(pentyloxy)-*p*-terphenyl-4-yl]carbonyl]-*L*-ornithyl-*L*-threonyl-*trans*-4-hydroxy-*L*-prolyl-(*S*)-4-hydroxy-4-(*p*-hydroxyphenyl)-*L*-threonyl-*L*-threonyl-(3*S*,4*S*)-3-hydroxy-4-methyl-*L*-proline cyclic (6→1)-peptide

anidulafungine

N-[(2*R*,6*S*,9*S*,11*R*,12*R*,14*aS*,15*S*,16*S*,20*S*,23*S*,25*aS*)-23-[(1*S*,2*S*)-1,2-dihydroxy-2-(4-hydroxyphényl)éthyl]-2,11,12,15-tétrahydroxy-6,20-bis[(1*R*)-1-hydroxyéthyl]-16-méthyl-5,8,14,19,22,25-hexaoxotétracosahydro-1*H*-dipyrrolo[2,1-*c*:2',1'-*l*][1,4,7,10,13,16]hexaazacyclohénicosén-9-yl]-4''-(pentyloxy)-1,1':4',1''-terphényle-4-carboxamide

anidulafungina

péptido (6→1)-cíclico (4*R*,5*R*)-4,5-dihidroxi-*N*²-[4''-(pentiloxi)-*p*-terfenil-4-il]carbonil]-*L*-ornitil-*L*-treonil-*trans*-4-hidroxi-*L*-prolil-(*S*)-4-hidroxi-4-(*p*-hidroxifenil)-*L*-treonil-*L*-treonil-(3*S*,4*S*)-3-hidroxi-4-metil-*L*-prolina

$C_{58}H_{73}N_7O_{17}$ **artemimolum**


artemimol

(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*S*,12*R*,12*aR*)-decahydro-3,6,9-triméthyl-3,12-époxy-12*H*-pyrano[4,3-*j*]-1,2-benzodioxépin-10-ol

arténimol

(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*S*,12*R*,12*aR*)-3,6,9-triméthyl-décahydro-3,12-époxy-pyrano[4,3-*j*]-1,2-benzodioxépin-10-ol

artemimol

(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*S*,12*R*,12*aR*)-decahydro-3,6,9-triméthyl-3,12-époxi-12*H*-pirano[4,3-*j*]-1,2-benzodioxépin-10-ol $C_{15}H_{24}O_5$ 

atizoramum


atizoram

tetrahydro-5-[4-methoxy-3-[(1*S*,2*S*,4*R*)-2-norbornyloxy]phenyl]-2(1*H*)-pyrimidinone

atizoram

5-[3-[[[(1*S*,2*S*,4*R*)-bicyclo[2.2.1]hept-2-yl]oxy]-4-méthoxyphényl]=tétrahydropyrimidin-2(1*H*)-one

atizoram

tetrahidro-5-[4-metoxi-3-[(1*S*,2*S*,4*R*)-2-norborniloxi]fenil]-2(1*H*)-pirimidinona $C_{18}H_{24}N_2O_3$ **atliprofenum**


atliprofen

(±)-*p*-3-thienylhydratropic acid

atliprofène

acide (*RS*)-2-[4-(thiophén-3-yl)phényl]propanoïque

atliprofeno

ácido (±)-*p*-3-tienilhidratrópico $C_{13}H_{12}O_2S$ **beclamidum**


beclamide

N-benzyl-β-chloropropionamide

béclamide

N-benzyl-3-chloropropanamide

beclamida

N-bencil-β-cloropropionamida $C_{10}H_{12}ClNO$ 

bexlosteridum


bexlosteride

(4a*R*,10b*R*)-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[*f*]quinolin-3(2*H*)-one

bexlostéríde

(4a*R*,10b*R*)-8-chloro-4-méthyl-1,4,4a,5,6,10b-hexahydrobenzo[*f*]quinoléin-3(2*H*)-one

bexlosterida

(4a*R*,10b*R*)-8-cloro-1,4,4a,5,6,10b-hexahidro-4-metilbenzo[*f*]quinolin-3(2*H*)-onaC₁₄H₁₆ClNO**bicifadinum**


bicifadine

(±)-1-*p*-tolyl-3-azabicyclo[3.1.0]hexane

bicifadine

(1*RS*,5*SR*)-1-(4-méthylphényl)-3-azabicyclo[3.1.0]hexane

bicifadina

(±)-1-*p*-tolil-3-azabíciclo[3.1.0]hexanoC₁₂H₁₅N**bornelonum**

bornelone


5-(3,3-dimethyl-2-norbornylidene-3-penten-2-one

bornélonge

(3*E*)-5-[(1*RS*,2*E*,4*SR*)-3,3-diméthylbicyclo[2.2.1]hept-2-ylidène]pent-3-én-2-one

bornelona

5-(3,3-dimetil-2-norbornilideno-3-penten-2-ona

C₁₄H₂₀O

cadrofloxacinum

cadrofloxacine


(-)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-1,4-dihydro-7-[(S)-3-methyl-1-piperazinyl]-4-oxo-3-quinolinecarboxylic acid

cadrofloxacine

(-)-acide 1-cyclopropyl-8-(difluorométhoxy)-6-fluoro-7-[(3S)-3-méthylpipérazin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

cadrofloxacino

ácido (-)-1-ciclopropil-8-(difluorometoxi)-6-fluoro-1,4-dihidro-7-[(S)-3-metil-1-piperazinil]-4-oxo-3-quinolinacarboxílico

 $C_{19}H_{20}F_3N_3O_4$ **cefmatilenum**


cefmatilène

(-)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[*(v*-triazol-4-ylthio)methyl]thio]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7²-(*Z*)-oxime

cefmatilène

(-)-acide (6*R*,7*R*)-7-[[*(Z*)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acétyl]=amino]-8-oxo-3-[[[(1*H*-1,2,3-triazol-4-yl)sulfanyl]méthyl]sulfanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

cefmatileno

7²-(*Z*)-oxima del ácido (-)-(6*R*,7*R*)-7-[2-(2-amino-4-tiazolil)glioxilamido]-8-oxo-3-[[*(v*-triazol-4-iltio)metil]tio]-5-tia-1-azabíciclo[4.2.0]oct-2-eno-2-carboxílico $C_{15}H_{14}N_8O_5S_4$ **ciadoxum**


ciadox

cyanoacetic acid (2-quinoxalinylmethylene)hydrazide *N*¹,*N*⁴-dioxide

ciadox

2-cyano-2'-[(*E*)-(quinoxalin-2-yl 1,4-dioxyde)méthylène]acétohydrazide

ciadox

*N*¹,*N*⁴-dióxido de la (2-quinoxalilmetileno)hidrazida del ácido cianoacético $C_{12}H_9N_5O_3$ 

cilengitidum

cilengitide


cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N-methyl-L-valyl)

cilengitide

cyclo[L-arginyl-glycyl-L-α-aspartyl-D-phénylalanyl-(N-méthyl-L-valyl)]

cilengitida

ciclo(L-arginilglicil-L-a-aspartil-D-fenilalanil-N-metil-L-valil)

 $C_{27}H_{40}N_8O_7$ **cipemastatum**


cipemastat

(α*R*,β*R*)-β-(cyclopentylmethyl)-γ-oxo-α-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-1-piperidinebutyrylhydroxamic acid

cipémastat

(2*R*,3*R*)-3-(cyclopentylméthyl)-*N*-hydroxy-4-oxo-4-(pipéridin-1-yl)-2-[(3,4,4-triméthyl-2,5-dioxoimidazolidin-1-yl)méthyl]butanamide

cipemastat

ácido (α*R*,β*R*)-β-(ciclopentilmetil)-γ-oxo-α-[(3,4,4-trimetil-2,5-dioxo-1-imidazolidinil)metil]-1-piperidinabutirotirohidroxámico $C_{22}H_{36}N_4O_5$ **cloperastinum**

cloperastine


1-[2-[(*p*-chloro-α-phenylbenzyl)oxy]]piperidine

clopérasine

1-[2-[(*RS*)-(4-chlorophényl)phénylméthoxy]éthyl]pipéridine

cloperastina

1-[2-[(4-cloro-α-fenilbencil)oxi]etil]piperidina

 $C_{20}H_{24}ClNO$ and enantiomer
et énantiomère
y enantiómero

clorexolonum

clorexolone


6-chloro-2-cyclohexyl-3-oxo-5-isoindolinesulfonamide

clorexolone

6-chloro-2-cyclohexyl-3-oxo-2,3-dihydro-1*H*-isoindole-5-sulfonamide

clorexolona

6-cloro-2-ciclohexil-3-oxo-5-isoindolinosulfonamida

 $C_{14}H_{17}ClN_2O_3S$ **cloroperonum**


cloroperone

4-[4-(*p*-chlorobenzoyl)piperidino]-4'-fluorobutyrophenone

cloropérone

4-[4-(4-chlorobenzoyl)pipéridin-1-yl]-1-(4-fluorophényl)butan-1-one

cloroperona

4-[4-(*p*-clorobenzoil)piperidino]-4'-fluorobutirotfenona $C_{22}H_{23}ClFNO_2$ **corticotropinum zinci hydroxydum**

corticotropin zinc hydroxide

a preparation of purified corticotropin adsorbed on zinc hydroxide

corticotropine hydroxyde de zinc

préparation de corticotropine purifiée adsorbée sur l'hydroxyde de zinc

corticotropina hidróxido de zinc

preparación de corticotropina purificada adsorbida en hidróxido de zinc

cresotamidum

cresotamide


2,3-cresotamide

crésotamide

2-hydroxy-3-méthylbenzamide

cresotamida

2,3-cresotamida

 $C_8H_9NO_2$ 

difenidolum

difenidol


 α,α -diphenyl-1-piperidinebutanol

difénidol

1,1-diphényl-4-(pipéridin-1-yl)butan-1-ol

difenidol

1,1-difenil-4-piperidinobutanol

 $C_{21}H_{27}NO$ **diosminum**


diosmin

3',5,7-trihydroxy-4'-methoxyflavone 7-[6-O-(6-deoxy- α -L-mannopyranosyl)- β -D-glucopyranoside]

diosmine

7-[[6-O-(6-désoxy- α -L-mannopyranosyl)- β -D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-méthoxyphényl)-4H-1-benzopyran-4-one

diosmína

7-[6-O-desoxi- α -L-manopiranosil]- β -D-glucopiranosido de 3',5,7-trihidroxi-4'-metoxiflavona $C_{28}H_{32}O_{15}$ **divabuterolum**


divabuterol

(±)-5-[2-(*tert*-butylamino)-1-hydroxyethyl]-*m*-phenylene dipivalate

divabutérol

bis(2,2-diméthylpropanoate) de 5-[(1*RS*)-2-[(1,1-diméthyléthyl)amino]-1-hydroxyéthyl]-1,3-phénylène

divabuterol

dipivalato de (±)-5-[2-(*terc*-butilamino)-1-hidroxietil]-*m*-fenileno $C_{22}H_{35}NO_5$ 

eledoisinum

eledoisin 5-oxo-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-aspartyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-leucyl-L-methioninamide


elédôisine

(5-oxo-L-prolyl)-L-prolyl-L-seryl-L-lysyl-L-aspartyl-L-alanyl-L-phénylalanyl-L-isoleucyl-glycyl-L-leucyl-L-méthioninamide

eledoisina

5-oxo-L-prolil-L-prolil-L-seril-L-lisil-L-aspartil-L-alanil-L-fenilalanil-L-isoleucilglicil-L-leucil-L-metioninamida

$C_{54}H_{85}N_{13}O_{15}S$

**eritriyli tetranitras**

eritryl tetranitrate

erythritol tetranitrate


tétranitrate d'éritrityle

tétranitrate de (2*R*,3*S*)-butane-1,2,3,4-tétryle

tetranitrato de eritritilo

tetranitrato de eritritol

$C_4H_6N_4O_{12}$



esketaminum
esketamine

(S)-2-(*o*-chlorophenyl)-2-(methylamino)cyclohexanone


eskétamine

(2S)-2-(2-chlorophényl)-2-(méthylamino)cyclohexanone

esketamina

(S)-2-(*o*-clorofenil)-2-(metilamino)ciclohexanona

C₁₃H₁₆ClNO



etanerceptum
etanercept

1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ 1-chain Fc fragment), dimer

étanercept

1-235-récepteur du facteur de nécrose tumorale (humain)-236-467-immunoglobuline G1 (chaîne γ 1 du fragment Fc humain), dimère

etanercept

dímero de la proteína de fusión del 1-235 receptor del factor de necrosis tumoral (humano) con la 236-467-immunoglobulina G1 (cadena γ 1 del fragmento Fc humano)

C₂₂₂₄H₃₄₇₂N₆₁₈O₇₀₁S₃₆ (monomer)

LPAQVAFTPY	APEPGSTCRL	REYYDQTAQM	CCSKCSPGQH
AKVFCTKTS	TVCDSCEDST	YTQLWNWVPE	CLSCGSRCSS
DQVETQACTR	EQNRICTCRP	GWYCALSKE	GCRLCAPLRK
CRPGFGVARP	GTETSDVVCK	PCAPGTFST	TSSTDICRPH
QICNVVAIPG	NASMDAVCTS	TSPTSRMAPG	AVHLPQPVST
RSQHTQPTPE	PSTAPSTSFL	LPMGPSPPAE	GSTGDEPKSC
DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	LMISRTPEVT
CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK
GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	GFYPSTDAVE
WESNGQPENN	YKTTTPVLDS	DGSFFLYSKL	TVDKSRWQQG
NVFSCSVME	ALHNHYTQKS	LSLSPGK	

2

exatecanum


exatecan

(1*S*,9*S*)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10*H*,13*H*-benzo[*de*]pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-10,13-dione

exatécan

(1*S*,9*S*)-1-amino-9-éthyl-5-fluoro-9-hydroxy-4-méthyl-1,2,3,9,12,15-hexahydro-10*H*,13*H*-benzo[*de*]pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-10,13-dione

exatecán

(1*S*,9*S*)-1-amino-9-etil-5-fluoro-1,2,3,9,12,15-hexahidro-9-hidroxi-4-metil-10*H*,13*H*-benzo[*de*]pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-10,13-dionaC₂₄H₂₂FN₃O₄**exepanolum**


exepanol

(±)-*cis*-2,3,4,5-tetrahydro-3-(methylamino)-1-benzoxepin-5-ol

exépanol

(3*RS*,5*SR*)-3-(méthylamino)-2,3,4,5-tétrahydro-1-benzoxépin-5-ol

exepanol

(±)-*cis*-2,3,4,5-tetrahydro-3-(metilamino)-1-benzoxepin-5-olC₁₁H₁₅NO₂**falnidamolum**


falnidamol

8-(3-chloro-4-fluoroanilino)-2-[(1-methyl-4-piperidyl)amino]pyrimido=[5,4-*d*]pyrimidine

falnidamol

*N*⁸-(3-chloro-4-fluorophényl)-*N*²-(1-méthylpipéridin-4-yl)pyrimido=[5,4-*d*]pyrimidine-2,8-diamine

falnidamol

8-(3-cloro-4-fluoroanilino)-2-[(1-metil-4-piperidil)amino]pirimido=[5,4-*d*]pirimidinaC₁₈H₁₉ClFN₇

fenaclonum


fenaclon

3-chloro-*N*-phenethylpropionamide

fénaclone

3-chloro-*N*-(2-phényléthyl)propanamide

fenaclona

3-cloro-*N*-fenetilpropionamida $C_{11}H_{14}ClNO$ **fenoprofenum**


fenoprofen

(±)-*m*-phenoxyhydratropic acid

fénoprofène

acide (*RS*)-2-(3-phénoxyphényl)propanoïque

fenoprofeno

ácido (±)-*m*-fenoxihidratrópico $C_{15}H_{14}O_3$ **finrozolum**


finrozole

p-[3-(*p*-fluorophenyl)-2-hydroxy-1-(1*H*-1,2,4-triazol-1-yl)propyl]benzonitrile

finrozole

4-[3-(4-fluorophényl)-2-hydroxy-1-(1*H*-1,2,4-triazol-1-yl)propyl]benzonitrile

finrozol

p-[3-(*p*-fluorofenil)-2-hidroxi-1-(1*H*-1,2,4-triazol-1-il)propil]benzonitrilo $C_{18}H_{15}FN_4O$ 

fluquazonum


fluquazone

6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)-2(1*H*)-quinazolinone

fluquazone

6-chloro-4-phényl-1-(2,2,2-trifluoroéthyl)quinazolin-2(1*H*)-one

flucuazona

6-cloro-4-fenil-1-(2,2,2-trifluoroetil)-2(1*H*)-quinazolinona $C_{16}H_{10}ClF_3N_2O$ **fosfructosum**

fosfructose


D-fructose 1,6-bis(dihydrogen phosphate)

fosfructose

1,6-bis(dihydrogénophosphate) de D-*arabino*-2-hexulofuranose

fosfructosa

1,6-bis(dihidrógenofosfato) de D-fructosa

 $C_6H_{14}O_{12}P_2$ **frakefamidum**


frakefamide

L-tyrosyl-D-alanyl-*p*-fluoro-L-phenylalanyl-L-phenylalaninamide

frakéfamide

L-tyrosyl-D-alanyl-(4-fluoro-L-phénylalanyl)-L-phénylalaninamide

frakefamida

L-tirosil-D-alanil-*p*-fluoro-L-fenilalanil-L-fenilalaninamida $C_{30}H_{34}FN_5O_5$ 

ganstigminum
ganstigmine

(4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-*b*]indol-6-yl *o*-ethylcarbanilate


ganstigmine

(2-éthylphényl)carbamate de (4a*S*,9a*S*)-2,4a,9-triméthyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-*b*]indol-6-yle

ganstigmina

o-etilcarbanilato de (4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahidro-2,4a,9-trimetil-1,2-oxazino[6,5-*b*]indol-6-ilo

C₂₂H₂₇N₃O₃



gemifloxacinum
gemifloxacin

(±)-7-[3-(aminométhyl)-4-oxo-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, 7⁴-(*Z*)-(O-methyloxime)


gémifloxacine

acide 7-[(3*RS*,4*Z*)-3-(aminométhyl)-4-(méthoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylique

gemifloxacino

7⁴-(*Z*)-(O-metiloxima) del ácido (±)-7-[3-(aminometil)-4-oxo-1-pirrolidinil]-1-ciclopropil-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílico

C₁₈H₂₀FN₅O₄



glutaurinum


glutaurine

N-(2-sulfoethyl)-L-glutamine

glutaurine

acide (2*S*)-2-amino-5-oxo-5-[(2-sulfoéthyl)amino]pentanoïque

glutaurina

N-(2-sulfoetil)-L-glutamina $C_7H_{14}N_2O_6S$ **guaifyllinum**


guaifylline

3-(*o*-methoxyphenoxy)-1,2 propanediol compound with theophylline

guaifylline

composé équimoléculaire de 1,3-diméthyl-3,7-dihydro-1*H*-purine-2,6-dione et de (2*RS*)-3-(2-méthoxyphénoxy)propane-1,2-diol

guaifilina

3-(*o*-metoxifenoxi)-1,2 propanodiol compuesto con teofilina $C_7H_8N_4O_2 \cdot C_{10}H_{14}O_4$ **halazonum**


halazone

p-(dichlorosulfamoyl)benzoic acid

halazone

acide 4-(dichlorosulfamoyl)benzoïque

halazona

ácido-*p*-(diclorosulfamoil)benzoico $C_7H_5Cl_2NO_4S$ 

ibritumomabum tiuxetanum

ibritumomab tiuxetan


immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDEC-Y2B8 γ 1-chain), disulfide with mouse monoclonal IDEC-Y2B8 κ -chain, dimer, *N*-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-*N*-[2-[bis(carboxymethyl)amino]propyl]glycine conjugate

ibritumomab tiuxétan

produit de la réaction entre l'immunoglobuline G1, anti-(antigène CD20 humain) (chaîne γ 1 de l'anticorps monoclonal de souris IDEC-Y2B8), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IDEC-Y2B8 et la *N*-[2-[bis(carboxyméthyl)amino]-3-(4-isothiocyanatophényl)propyl]-*N*-[2-[bis(carboxyméthyl)amino]propyl]glycine

ibritumomab tiuxetán

N-[[4-[(2*S*)-2-[bis(carboximetil)amino]-3-[[[(2*RS*)-2-[bis(carboximetil)amino]propil](carboximetil)amino]propil]fenil]tiocarbamoil]=immunoglobulina G1, anti-(antígeno CD20 humano) (cadena γ 1 del anticuerpo monoclonal quimérico hombre-ratón IDEC-Y2B8), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón IDEC-Y2B8

**idremcinalum**

idremcinal


8,9-didehydro-*N*-demethyl-9-deoxy-6-deoxy-6,9-epoxy-*N*-isopropylerythromycin

idremcinal

(2*R*,3*R*,4*S*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-3,4-dihydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,6-didésoxy- α -*L*-ribo-hexopyranosyl)oxy]-11-[3-[méthyl(1-méthyléthyl)amino]-3,4,6-tridésoxy- β -*D*-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

idremcinal

8,9-dideshidro-*N*-desmetil-9-desoxo-6-desoxi-6,9-epoxi-*N*-isopropileritromicina

C₃₉H₆₉NO₁₂

ilodecakinum

ilodecakin

interleukin 10 (human clone pH15C)

ilodécakine

interleukine 10 (clone humain pH15C)

ilodecakina

interleuquina 10 (clon humano pH15C)

SPGQGTQSEN	SCTHFPGNLP	NMLRDLRDAF	SRVKTFQMK
DQLDNLLKE	SLLEDFKGYL	GCQALSEMIQ	FYLEEVMPQA
ENQDPDIKAH	VNSLGENLKT	LRLRLRRCHR	FLPCENKSKA
VEQVKNAFNK	LQEKGIYKAM	SEFDIFINYI	EAYMTMKIRN

izonsteridum


izonsteride

(4*aR*,10*bR*)-8-[(4-ethyl-2-benzothiazolyl)thio]-1,4,4*a*,5,6,10*b*-hexahydro-4,10*b*-dimethylbenzo[*f*]quinolin-3(2*H*)-one

izonstéride

(4*aR*,10*bR*)-8-[(4-éthylbenzothiazol-2-yl)sulfanyl]-4,10*b*-diméthyl-1,4,4*a*,5,6,10*b*-hexahydrobenzo[*f*]quinoléin-3(2*H*)-one

izonsterida

(4*aR*,10*bR*)-8-[(4-etil-2-benzotiazolil)tio]-1,4,4*a*,5,6,10*b*-hexahidro-4,10*b*-dimetilbenzo[*f*]quinolin-3(2*H*)-onaC₂₄H₂₆N₂OS₂**kebuzonum**

kebuzone


4-(3-oxobutyl)-1,2-diphenyl-3,5-pyrazolidinedione

kébuzone

4-(3-oxobutyl)-1,2-diphénylpyrazolidine-3,5-dione

kebuzona

4-(3-oxobutil)-1,2-difenil-3,5-pirazolidinadiona

C₁₉H₁₈N₂O₃

lasofoxifenum


lasofoxifene

(-)-*cis*-5,6,7,8-tetrahydro-6-phenyl-5-[*p*-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthol

lasofoxifène

(-)-(5*RS*,6*SR*)-6-phényl-5-[4-[2-(pyrrolidin-1-yl)éthoxy]phényl]-5,6,7,8-tétrahydronaphtalén-2-ol

lasofoxifeno

(-)-*cis*-5,6,7,8-tetrahidro-6-fenil-5-[*p*-[2-(1-pirrolidinil)etoksi]fenil]-2-naftolC₂₈H₃₁NO₂**liaterminum**


liatermin

N-methionylneurotrophic factor (human glial-derived), dimer

liatermine

N-méthionylfacteur neurotrophique (humain, dérivé de la glia), dimère

liatermina

dímero del factor *N*-metionilneurotrófico (humano derivado de la glia)C₁₂₉₀H₂₁₁₀N₄₂₀O₃₉₄S₁₈**licarbazepinum**


licarbazepine

10,11-dihydro-10-hydroxy-5*H*-dibenz[*b*,*f*]azepine-5-carboxamide

licarbazépine

(10*RS*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azépine-5-carboxamide

licarbazepina

10,11-dihidro-10-hidroxi-5*H*-dibenz[*b*,*f*]azepina-5-carboxamidaC₁₅H₁₄N₂O₂

mepolizumabum

mepolizumab

immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 γ 1-chain), disulfide with human-mouse monoclonal SB-240563 κ -chain, dimer

mépolizumab

immunoglobuline G1, anti-(interleukine 5 humaine) (chaîne γ 1 de l'anticorps monoclonal de souris SB-240563 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris SB-240563 humanisé

mepolizumab

inmunoglobulina G1, anti-(interleukina 5 humana) (cadena γ 1 del anticuerpo monoclonal de ratón SB-240563 humanizado), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón SB-240563 humanizado**metamfepramonum**

metamfepramone


2-(dimethylamino)propiofenone

métamfépramone

(2*RS*)-2-(diméthylamino)-1-phénylpropan-1-one

metanfepramona

2-(dimetilamino)propiofenona

C₁₁H₁₅NO**meticillinum**

meticillin


6-(2,6 dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

mécicilline

acide (2*S*,5*R*,6*R*)-6-[(2,6-diméthoxybenzoyl)amino]-3,3-diméthyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylique

meticilina

ácido 6-(2,6-dimetoxibenzamido)-3,3-dimetil-7-oxo-4-tia-1-azabicyclo-[3.2.0]heptano-2-carboxílico

C₁₇H₂₀N₂O₆S**moquizonum**

moquizone



2,3-dihydro-1-(morpholinoacetyl)-3-phenyl-4(1*H*)-quinazolinone

moquizone

1-(morpholin-4-ylacétyl)-3-phényl-2,3-dihydroquinazolin-4(1*H*)-one

moquizona

1-(2-morfolinoacetil)-3-fenil-2,3-dihidro-4-(1*H*)-quinazolinona

**nabilonum**

nabilone



(±)-*trans*-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9*H*-dibenzo[*b,d*]pyran-9-one

nabilone

(6*aRS*,10*aRS*)-3-(1,1-diméthylheptil)-1-hydroxy-6,6-diméthyl-6,6a,7,8,10,10a-hexahydro-9*H*-dibenzo[*b,d*]pyran-9-one

nabilona

(±)-*trans*-3-(1,1-dimetilheptil)-6,6a,7,8,10,10a-hexahidro-1-hidroxi-6,6-dimetil-9*H*-dibenzo[*b,d*]piran-9-ona



and enantiomer
et énantiomère
y enantiómero

nonabinum

nonabine



7-(1,2-dimethylheptyl)-2,2-dimethyl-4-(4-pyridyl)-2*H*-1-benzopyran-5-ol

nonabine

7-(1,2-diméthylheptil)-2,2-diméthyl-4-(pyridin-4-yl)-2*H*-1-benzopyran-5-ol

nonabina

7-(1,2-dimetilheptil)-2,2-dimetil-4-(4-piridil)-2*H*-1-benzopiran-5-ol



norgesteronum


norgesterone

17-hydroxy-19-nor-17 α -pregna-5(10),20-dien-3-one

norgestérone

17-hydroxy-19-nor-17 α -prégna-5(10),20-dién-3-one

norgesterona

17-hidoxi-19-nor-17 α -pregna-5(10),20-dieno-3-ona $C_{20}H_{28}O_2$ **odalprofenum**


odalprofen

methyl ($\pm$)-*m*-(α -imidazol-1-ylbenzyl)hydratropate

odalprofène

mélange d'isomères du 2-[3-[(1*H*-imidazol-1-yl)phénylméthyl]phényl]propanoate de méthyle

odalprofeno

($\pm$)-*m*-(α -imidazol-1-ilbencil)hidratropato de metilo $C_{20}H_{20}N_2O_2$ **olanexidinum**

olanexidine


1-(3,4-dichlorobenzyl)-5-octylbiguanide

olanexidine

1-(3,4-dichlorobenzyl)-5-octylbiguanide

olanexidina

1-(3,4-diclorobencil)-5-octilbiguanida

 $C_{17}H_{27}Cl_2N_5$ 

oletimolum


oletimol

o-(*N*-benzylacetimidoyl)phenol

olétimol

2-[(*E*)-1-(benzylimino)éthyl]phénol

oletimol

o-(*N*-bencilacetimidoil)fenolC₁₅H₁₅NO**pentiapinum**


pentiapine

5-(4-methyl-1-piperazinyl)imidazo[2,1-*b*][1,3,5]benzothiadiazepine

pentiapine

5-(4-méthylpipérazin-1-yl)imidazo[2,1-*b*][1,3,5]benzothiadiazépine

pentiapina

5-(4-metil-1-piperazinil)imidazo[2,1-*b*][1,3,5]benzotiadiazepinaC₁₅H₁₇N₅S**pibrozelesinum**


pibrozelesin

methyl (*S*)-8-(bromomethyl)-3,6,7,8-tetrahydro-4-hydroxy-2-methyl-6-[(5,6,7-trimethoxyindol-2-yl)carbonyl]benzo[1,2-*b*:4,3-*b'*]dipyrrole-1-carboxylate, 4-methyl-1-piperazinecarboxylate (ester)

pibrozelésine

(8*S*)-8-(bromométhyl)-2-méthyl-4-[[4-méthylpipérazin-1-yl]carbonyl]oxy]-6-[(5,6,7-triméthoxy-1*H*-indol-2-yl)carbonyl]-3,6,7,8-tétrahydrobenzo[1,2-*b*:4,3-*b'*]dipyrrole-1-carboxylate de méthyle

pibrozelesina

(8*S*)-(bromometil)-3,6,7,8-tetrahidro-2-metil-4-[[4-metil-1-piperazinil]=carbonil]oxi]-6-[(5,6,7-trimetoxi-1*H*-indol-2-il)carbonil]benzo=[1,2-*b*:4,3-*b'*]dipirrol-1-carboxilato de metiloC₃₂H₃₆BrN₅O₈

pimecrolimusum

pimecrolimus


(3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26*aS*)-3-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-methoxycyclohexyl]-1-methylvinyl]-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26*a*-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone

pimécrolimus

(18*E*)-(1*R*,9*S*,12*S*,13*R*,14*S*,17*R*,21*S*,23*S*,24*R*,25*S*,27*R*)-12-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-méthoxycyclohexyl]-1-méthyléthényl]-17-éthyl-1,14-dihydroxy-23,25-diméthoxy-13,19,21,27-tétraméthyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ène-2,3,10,16-tétrone

pimecrolimús

(3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26*aS*)-3-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-cloro-3-metoxiciclohexil]-1-metilvinil]-8-etil-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26*a*-hexadecahidro-5,19-dihidroxi-14,16-dimetoxi-4,10,12,18-tetrametil-15,19-epoxi-3*H*-pirido[2,1-*c*][1,4]oxaazacicltricosina-1,7,20,21(4*H*,23*H*)-tetrona

C₄₃H₆₈ClNO₁₁**plauracinum**

plauracin

an antibiotic complex obtained from cultures of *Actinoplanes auranticolor* ATCC 31011

plauracine

antibiotique extrait de cultures d'*Actinoplanes auranticolor* (ATCC 31011) composé principalement d'une lactone macrocyclique et d'un depsipeptide

plauracina

antibiótico complejo, mezcla de dos componentes principales, obtenido a partir de cultivos de *Actinoplanes auranticolor* ATCC 31011

prazarelixum

prazarelix


N-acetyl-3-(2-naphthyl)-D-alanyl-*p*-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-*p*-[(5-amino-*s*-triazol-3-yl)amino]-L-phenylalanyl-*p*-[(5-amino-*s*-triazol-3-yl)amino]-D-phenylalanyl-L-leucyl-*N*⁶-isopropyl-L-lysyl-L-prolyl-D-alaninamide

prazarélix

[*N*-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-[4-[(5-amino-1-*H*-1,2,4-triazol-3-yl)amino]-L-phénylalanyl]-[4-[(5-amino-1-*H*-1,2,4-triazol-3-yl)amino]-D-phénylalanyl]-L-leucyl-[*N*⁶-(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide

prazarelix

N-acetil-3-(2-naftil)-D-alanil-*p*-cloro-D-fenilalanil-3-(3-piridil)-D-alanil-L-seril-*p*-[(5-amino-*s*-triazol-3-il)amino]-L-fenilalanil-*p*-[(5-amino-*s*-triazol-3-il)amino]-D-fenilalanil-L-leucil-*N*⁶-isopropil-L-lisil-L-prolil-D-alaninamida

C₈₀H₁₀₂ClN₂₃O₁₂**ranpirnasum**

ranpirnase

ribonuclease (*Rana pipiens*)

ranpirnase

ribonucléase (*Rana pipiens*)

ranpirnasa

ribonucleasa (*Rana pipiens*)C₅₂₀H₈₁₂N₁₄₂O₁₅₆S₉

```

EDWLTFQKKH  ITNTRDVDCD  NIMSTNLFHC  KDKNTFIYSR
PEPVKAICKG  IIASKNVLT  SEFYLSDCNV  TSRPCKYKLG
KSTNKFCVTC  ENQAPVHFVG  VGSC

```

rasburicasum

rasburicase

urate oxydase (tetramer of the *N*-acetylpolypeptide of 301 amino acids)

rasburicase

urate oxydase (tétramère du *N*-acétylpolypeptide de 301 amino-acides)

rasburicasa

urato oxidasa (tétramero del *N*-acetilpolipeptido de 301 amino-ácidos)

C₁₅₂₃H₂₃₈₃N₄₁₇O₄₆₂S₇ (monomer)

				Ac
SAVKAARYGK	DNVRVYKVHK	DEKTVQTVY	EMTVCVLLG	
EIETSYTKAD	NSVIVATDSI	KNTIYITAKQ	NPVTPPELFG	
SILGTHFIEK	YNHIHAAHVN	IVCHRWRMD	IDGKPHPHSF	
IRDSEEKRV	QVDVVEGKGI	DIKSSLSGLT	VLKSTNSQFW	
GFLRDEYTTL	KETWDRILST	DVDATWQWKN	FSGLQEVRS	
VPKFDATWAT	AREVTLKTFA	EDNSASVQAT	MYKMAEQILA	
RQQLIETVEY	SLPNKHFEI	DLSWHKGLQN	TGKNAEVFAP	
QSDPNGLIKC	TVGRSSLKSK	L		

rovelizumabum

rovelizumab

immunoglobulin G4, anti-(human CD11 (antigen)/integrin β_2) (human-mouse monoclonal Hu23F2G γ 4-chain), disulfide with human-mouse monoclonal Hu23F2G κ -chain, dimer

rovélizumab

immunoglobuline G4, anti-(antigène CD11 humain ou intégrine β_2) (chaîne γ 4 de l'anticorps monoclonal de souris Hu23F2G, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris Hu23F2G, humanisé

rovelizumab

inmunoglobulina G4, anti-(antígeno CD11 humano o integrina β_2) (cadena γ 4 del anticuerpo monoclonal de ratón Hu23F2G, humanizado), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón Hu23F2G, humanizado

sarakalimum

sarakalim


N-[[2,2-dimethyl-4-(2-oxo-1(2*H*)-pyridyl)-6-(trifluoromethyl)-2*H*-1-benzopyran-3-yl]methyl]acetohydroxamic acid

sarakalim

N-[[2,2-diméthyl-4-(2-oxopyridin-1(2*H*)-yl)-6-(trifluorométhyl)-2*H*-chromén-3-yl]méthyl]-*N*-hydroxyacétamide

sarakalim

ácido *N*-[[2,2-dimetil-4-(2-oxo-1(2*H*)-piridil)-6-(trifluorometil)-2*H*-1-benzopiran-3-il]metil]acetohidroxámico

C₂₀H₁₉F₃N₂O₄

selamectinum

selamectin


(2*aE*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17*aR*,20*aR*,20*bS*)-6'-cyclohexyl-7-[(2,6-dideoxy-3-*O*-methyl- α -L-*arabino*-hexopyranosyl)oxy]-3',4',5',6,6',7,10,11,14,15,20*a*,20*b*-dodecahydro-20*b*-hydroxy-5',6,8,19-tetramethylspiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]=benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-17,20(17*aH*)-dione 20-oxime

sélamectine

(2*aE*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17*aR*,20*aR*,20*bS*)-6'-cyclohexyl-20*b*-hydroxy-5',6,8,19-tétraméthyl-7-[(3-*O*-méthyl-2,6-didésoxy- α -L-*arabino*-hexopyranosyl)oxy]-3',4',5',6,6',7,10,11,14,15,20*a*,20*b*-dodécahydro=spiro[11,15-méthano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadécène-13,2'-[2*H*]pyrane]-17,20(17*aH*)-dione (Z)-20-oxime

selamectina

20-oxima de (2*aE*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17*aR*,20*aR*,20*bS*)-6'-ciclohexil-7-[(2,6-didesoxi-3-*O*-metil- α -L-*arabino*-hexopiranosil)oxi]-3',4',5',6,6',7,10,11,14,15,20*a*,20*b*-dodecahidro-20*b*-hidroxi-5',6,8,19-tetrametilespiro[11,15-metano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]=benzodioxacyclooctadecin-13,2'-[2*H*]piran]-17,20(17*aH*)-diona

C₄₃H₆₃NO₁₁**sibrotuzumabum**

sibrotuzumab

immunoglobulin G1, anti-(human FAP (fibroblast activation protein)) (human-mouse monoclonal BIBH1 γ 1-chain), disulfide with human-mouse monoclonal BIBH1 κ -chain, dimer

sibrotuzumab

immunoglobuline G1, anti-(FAP (protéine activant le fibroblaste) humaine) (chaîne γ 1 de l'anticorps monoclonal de souris BIBH1, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BIBH1, humanisé

sibrotuzumab

inmunoglobulina G1, anti-(FAP humano (proteína de activación de los fibroblastos)) (cadena γ 1 del anticuerpo monoclonal de ratón BIBH1), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón BIBH1

siramesinum


siramesine

1'-[4-[1-(*p*-fluorophenyl)indol-3-yl]butyl]spiro[phthalan-1,4'-piperidine]

siramésine

1'-[4-[1-(4-fluorophényl)-1*H*-indol-3-yl]butyl]spiro[isobenzofurane-1(3*H*),4'-pipéridine]

siramesina

1'-[4-[1-(*p*-fluorofenil)indol-3-il]butil]espiro[ftalan-1,4'-piperidina] $C_{30}H_{31}FN_2O$ **sulisatinum**


sulisatin

3,3-bis(*p*-hydroxyphenyl)-7-methyl-2-indolinone bis(hydrogen sulfate) (ester)

sulisatine

bis(hydrogénosulfate) de 4,4'-(7-méthyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)diphényle

sulisatina

bis(hidrogenosulfato) (éster) de 3,3-bis(*p*-hidroxifenil)-7-metil-2-indolinona $C_{21}H_{17}NO_9S_2$ **talnetantum**


talnetant

N-[(*S*)- α -ethylbenzyl]-3-hydroxy-2-phenylcinchoninamide

talnétant

3-hydroxy-2-phényl-*N*-[(1*S*)-1-phénylpropyl]quinoléine-4-carboxamide

talnetant

N-[(*S*)- α -etilbencil]-3-hidroxi-2-fenilcinconinamida $C_{25}H_{22}N_2O_2$ 

tandaminum
tandamine

1-[2-(dimethylamino)ethyl]-9-ethyl-1,3,4,9-tetrahydro-1-methylthiopyrano[3,4-*b*]indole


tandamine

2-[(1*RS*)-9-éthyl-1-méthyl-1,3,4,9-tétrahydrothiopyrano[3,4-*b*]indol-1-yl]-*N,N*-diméthyléthanamine

tandamina

1-[2-(dimetilamino)etil]-9-etil-1,3,4,9-tetrahydro-1-metiltiópirano[3,4-*b*]indol

$C_{18}H_{26}N_2S$



teopranitolum
teopranitol

1,4:3,6-dianhydro-2-deoxy-2-[[3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)propyl]amino]-L-iditol 5-nitrate


téopranitol

nitrate de (3*S*,3*aS*,6*S*,6*aF*)-6-[[3-(1,3-diméthyl-2,6-dioxo-1,2,3,6-tétrahydro-7*H*-purin-7-yl)propyl]amino]hexahydrofuro[3,2-*b*]furan-3-yle

teopranitol

5-nitrato de 1,4:3,6-dianhidro-2-desoxi-2-[[3-(1,2,3,6-tetrahydro- 1,3-dimetil-2,6-dioxopurin-7-il)propil]amino]-L-iditol

$C_{16}H_{22}N_6O_7$



tesmilifenum
tesmilifene

2-[(α-phenyl-*p*-tolyl)oxy]triethylamine


tesmilifène

2-(4-benzylphénoxy)-*N,N*-diéthyléthanamine

tesmilifeno

2-[(α-fenil-*p*-tolil)oxi]triethylamina

$C_{19}H_{25}NO$



tezosentanum


tezosentan

N-[6-(2-hydroxyethoxy)-5-(*o*-methoxyphenoxy)-2-[2-(1*H*-tetrazol-5-yl)-4-pyridyl]-4-pyrimidinyl]-5-isopropyl-2-pyridinesulfonamide

tézosentan

N-[6-(2-hydroxyéthoxy)-5-(2-méthoxyphénoxy)-2-[2-(1*H*-tétrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-(1-méthyléthyl)pyridine-2-sulfonamide

tezosentano

N-[6-(2-hidroxiétoxi)-5-(*o*-metoxifenoxi)-2-[2-(1*H*-tetrazol-5-il)-4-piridil]-4-pirimidinil]-5-isopropil-2-piridinasulfonamida $C_{27}H_{27}N_9O_6S$ **ticarcillinum**


ticarcillin

N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-3-thiophenemalonamic acid

ticarcilline



acide (2*S*,5*R*,6*R*)-6-[[2*R*]-carboxy(thiophén-3-yl)acétyl]amino]-3,3-diméthyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylique

ticarcilina



ácido *N*-(2-carboxi-3,3-dimetil-7-oxo-4-tia-1-azabíciclo[3.2.0]hept-6-il)-3-tiofenomalónámico $C_{15}H_{16}N_2O_6S_2$ 

tienocarbium


tienocarbine	7,8,9,10-tetrahydro-1,9-dimethyl-6 <i>H</i> -pyrido[4,3- <i>b</i>]thieno[3,2- <i>e</i>]indole
tiénocarbine	1,9-diméthyl-7,8,9,10-tétrahydro-6 <i>H</i> -pyrido[4,3- <i>b</i>]thiéno[3,2- <i>e</i>]indole
tienocarbina	7,8,9,10-tetrahidro-1,9-dimetil-6 <i>H</i> -pirido[4,3- <i>b</i>]tieno[3,2- <i>e</i>]indol

**tocladesinum**

tocladesine	8-chloroadenosine 3',5'-cyclic phosphate
tocladésine	3',5'-hydrogénophosphate cyclique de 8-chloroadénosine
tocladesina	3',5'-hidrógenofosfato cíclico de 8-cloroadenosina

**triclofosum**

triclofos	2,2,2-trichloroethyl dihydrogen phosphate
triclofos	dihydrogénophosphate de 2,2,2-trichloroéthyle
triclofós	dihidrógenofosfato de 2,2,2-tricloroetilo



triflocinum


triflocin

4-(α,α,α -trifluoro-*m*-toluidino)nicotinic acid

triflocine

acide 4-[[3-(trifluorométhyl)phényl]amino]pyridine-3-carboxylique

triflocina

ácido 4-(α,α,α -trifluoro-*m*-toluidino)nicotínico $C_{13}H_9F_3N_2O_2$ **trimecainum**


trimecaine

N-(α -diethylaminoacetyl)-2,4,6-trimethylaniline

trimécaïne

2-(diéthylamino)-*N*-(2,4,6-triméthylphényl)acétamide

trimecaína

N-(α -diétilaminoacetil)-2,4,6-trimetilanilina $C_{15}H_{24}N_2O$ **troxacitabinum**


troxacitabine

(-)-1-[(2*S*,4*S*)-2-(hydroxyméthyl)-1,3-dioxolan-4-yl]cytosine

troxacitabine

(-)-4-amino-1-[(2*S*,4*S*)-2-(hydroxyméthyl)-1,3-dioxolan-4-yl]pyrimidin-2(1*H*)-one

troxacitabina

(-)-1-[(2*S*,4*S*)-2-(hidroximetil)-1,3-dioxolan-4-il]citosina $C_8H_{11}N_3O_4$ 


zolazepamum

zolazepam 4-(*o*-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpirazole[3,4-*e*][1,4]diazepin-7(1*H*)-one

zolazépam 4-(2-fluorophényl)-1,3,8-triméthyl-6,8-dihydropyrazolo[3,4-*e*][1,4]diazépin-7(1*H*)-one

zolazepam 4-(*o*-fluorofenil)-6,8-dihidro-1,3,8-trimetilpirazolo[3,4-*e*][1,4]diazepin-7(1*H*)-ona

C₁₅H₁₅FN₄O



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 38

Dénominations communes internationales recommandées (DCI Rec.): Liste 38

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 38

(WHO Drug Information, Vol. 11, No. 3, 1997)

p. 166 faralimomabum

faralimomab

replace the description by the following:

immunoglobulin G1, anti-(human interferon type I receptor) (mouse monoclonal 64G12 γ 1-chain), disulfide with mouse monoclonal 64G12 light chain, dimer

faralimomab

remplacer la description par la suivante:

immunoglobuline G1, anti-(récepteur humain des interférons de type I) (chaîne γ 1 de l'anticorps monoclonal de souris 64G12), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 64G12

faralimomab

sustitúyase la descripción por la siguiente:

inmunoglobulina G1, anti-(receptor humano de los interferones del tipo I) (cadena γ 1 del anticuerpo monoclonal de ratón 64G12), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 64G12

p. 169 keliximab

keliximab

replace the description by the following:

immunoglobulin G1, anti-(human CD4 (antigen)) (human-macaca monoclonal CE9.1 γ 1-chain), disulfide with human-macaca monoclonal CE9.1 λ -chain, dimer

kéliximab

remplacer la description par la suivante:

immunoglobuline G1, anti-(antigène CD4 humain) (chaîne γ 1 de l'anticorps monoclonal chimérique homme-macaque CE9.1), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal chimérique homme-macaque CE9.1

keliximab

sustituyase la descripción por la siguiente:

inmunoglobulina G1, anti-(antígeno CD4 humano) (cadena γ 1 del anticuerpo monoclonal hombre-macaco CE9.1), dímero del disulfuro con la cadena λ del anticuerpo monoclonal quimérico hombre-macaco CE9.1

p. 172 **lintuzumabum**

lintuzumab

*replace the description by the following:*immunoglobulin G1, anti-(human CD33 (antigen)) (human-mouse monoclonal HuM195 γ 1-chain), disulfide with human-mouse monoclonal HuM195 κ -chain, dimer

lintuzumab

*remplacer la description par la suivante:*immunoglobuline G1, anti-(antigène CD33 humain) (chaîne γ 1 de l'anticorps monoclonal de souris HuM195, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris HuM195, humanisé

lintuzumab

*sustituyase la descripción por la siguiente:*inmunoglobulina G1, anti-(antígeno CD33 humano) (cadena γ 1 del anticuerpo monoclonal hombre-ratón HuM195), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón HuM195**Recommended International Nonproprietary Names (Rec. INN): List 41****Dénominations communes internationales recommandées (DCI Rec.): Liste 41****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 41***(WHO Drug Information, Vol. 13, No. 1, 1999)*p. 53 **satumomabum**

satumomab

*replace the description by the following:*immunoglobulin G1, anti-(human tumor-associated glycoprotein 72) (mouse monoclonal B72.3 γ 1-chain), disulfide with mouse monoclonal B72.3 light chain, dimer

satumomab

*remplacer la description par la suivante:*immunoglobuline G1, anti-(glycoprotéine 72 humaine associée aux tumeurs) (chaîne γ 1 de l'anticorps monoclonal de souris B72.3), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris B72.3

satumomab

*sustitúyase la descripción por la siguiente:*inmunoglobulina G1, anti-(glicoproteína 72 humana asociada a los tumores) (cadena γ 1 del anticuerpo monoclonal de ratón B72.3), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón B72.3

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.